Ionis Pharmaceuticals INC (IONS) — SEC Filings

Overview

Ionis Pharmaceuticals INC (IONS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 17, 2025: On November 11, 2025, Ionis Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and other events. This filing details financial obligations and equity transactions for Ionis P

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 1 bearish, 41 neutral, 3 mixed. The dominant filing sentiment for Ionis Pharmaceuticals INC is neutral.

Filing Type Overview

Ionis Pharmaceuticals INC (IONS) has filed 26 8-K, 1 8-K/A, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (45)

• Ionis Pharmaceuticals Files 8-K on Agreements and Equity Sales — 8-K · Nov 17, 2025 Risk: medium
  On November 11, 2025, Ionis Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reporte
• Ionis Pharmaceuticals Files 8-K — 8-K · Nov 10, 2025 Risk: low
  On November 8, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and regulation FD disclosures, with no specific
• 8-K/A Filing — 8-K/A · Nov 3, 2025
• Ionis Pharmaceuticals Files 8-K on Financials — 8-K · Oct 29, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
• Ionis Revenue Soars 55% on New Drug Launches, Narrows Net Loss — 10-Q · Oct 29, 2025 Risk: medium
  Ionis Pharmaceuticals Inc. reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $740.38 million, up from $478
• Ionis Pharmaceuticals Files 8-K — 8-K · Sep 22, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on September 22, 2025, reporting on other events and financial statements. The filing does not contain specific financi
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Sep 2, 2025 Risk: low
  On September 2, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, indica
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Aug 21, 2025 Risk: low
  On August 21, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
• Ionis Pharmaceuticals Files 8-K on Financials — 8-K · Jul 30, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Ionis's Revenue Jumps 17%, But Net Loss Widens to $55.3M — 10-Q · Jul 30, 2025 Risk: medium
  Ionis Pharmaceuticals Inc. reported a significant increase in revenue for the quarter ended June 30, 2025, reaching $210.5 million, up from $180.2 million in th
• Ionis Pharmaceuticals Files 8-K on Director Changes and Compensation — 8-K · Jun 12, 2025 Risk: low
  On June 12, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filin
• Ionis Pharmaceuticals Files 8-K on Shareholder Votes & Financials — 8-K · Jun 10, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of security holders and financial statements as of June 5, 2
• Ionis Pharmaceuticals Files 8-K Report — 8-K · May 19, 2025 Risk: low
  On May 19, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Ionis Pharmaceuticals Files 8-K — 8-K · Apr 30, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on April 30, 2025, reporting on its results of operations and financial condition, and including financial statements a
• Ionis Pharmaceuticals Files Q1 2025 10-Q — 10-Q · Apr 30, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported revenue from various sources including Research and Developm
• Ionis Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
  Ionis Pharmaceuticals, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting on June 5, 2025. The filing details the com
• Ionis Pharmaceuticals Files 8-K for Material Agreement — 8-K · Mar 12, 2025 Risk: medium
  On March 11, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report to disclose the entry into a material definitive agreement. The filing does not provide speci
• Ionis Pharmaceuticals Files 8-K on Operations and Financials — 8-K · Feb 19, 2025 Risk: low
  On February 19, 2025, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition
• Ionis Pharmaceuticals Files 2024 Annual Report — 10-K · Feb 19, 2025 Risk: medium
  Ionis Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in Carlsbad, CA, reported on its financial p
• Ionis Pharmaceuticals Files 8-K — 8-K · Dec 20, 2024 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 19, 2024. The filing is related to "Other Events" an
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Ionis Pharmaceuticals Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
  On November 6, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Ionis Pharma Q3 Revenue Declines — 10-Q · Nov 6, 2024 Risk: medium
  Ionis Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported collaborative agreement revenue of $190.6 million for
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Sep 12, 2024 Risk: low
  On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," ind
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Sep 9, 2024 Risk: low
  On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific new transaction
• Ionis Pharmaceuticals Files 8-K — 8-K · Aug 1, 2024 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Ionis Pharmaceuticals Q2 2024: $300.6M Revenue, $1.4B Cash — 10-Q · Aug 1, 2024 Risk: medium
  Ionis Pharmaceuticals Inc. reported its Q2 2024 results, with total revenue for the six months ended June 30, 2024, reaching $300.6 million. The company's cash,
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Jun 18, 2024 Risk: low
  On June 18, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the submissi
• Ionis Pharmaceuticals Files 8-K on Shareholder Votes and Exhibits — 8-K · Jun 10, 2024 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The e
• Ionis Pharmaceuticals Files 8-K — 8-K · May 31, 2024 Risk: low
  Ionis Pharmaceuticals, Inc. filed an 8-K on May 31, 2024, to report other events and financial statements. The filing does not contain specific details about ne
• Ionis Pharmaceuticals Files 8-K on Operations — 8-K · May 7, 2024 Risk: low
  On May 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Ionis Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  IONIS PHARMACEUTICALS INC (IONS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Ionis Pharmaceuticals Inc. filed a 10-Q report for the period endi
• Ionis Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 25, 2024 Risk:
  IONIS PHARMACEUTICALS INC (IONS) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Ionis Pharmaceuticals, Inc. will hold its 2024 Annual Meeting
• Ionis Pharmaceuticals Files 8-K Report — 8-K · Apr 8, 2024 Risk: low
  On April 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
• Ionis Pharma Enters Material Agreement, Adjusts Officer Compensation — 8-K · Feb 29, 2024 Risk: medium
  Ionis Pharmaceuticals, Inc. filed an 8-K on February 29, 2024, reporting an event on February 28, 2024, concerning an entry into a material definitive agreement
• Ionis Pharma Files 8-K on Financial Condition — 8-K · Feb 21, 2024 Risk: low
  Ionis Pharmaceuticals Inc. filed an 8-K on February 21, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number
• Ionis Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk: IONS
  IONIS PHARMACEUTICALS INC (IONS) filed a Annual Report (10-K) with the SEC on February 21, 2024. Ionis Pharmaceuticals, Inc. filed its 2023 Form 10-K on Februar
• SC 13G Filing — SC 13G · Feb 14, 2024
• Vanguard Amends Ionis Pharma Stake, Maintains Passive Ownership — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, indicating its ownership of Ionis Pharmaceuticals Inc. common stock
• BB Biotech AG Amends IONIS PHARMACEUTICALS Stake — SC 13G/A · Feb 13, 2024 Risk: low
  BB Biotech AG, a Swiss investment company, filed an amended Schedule 13G/A on February 13, 2024, indicating a change in its beneficial ownership of IONIS PHARMA
• FMR LLC & Abigail Johnson Hold 15% Stake in Ionis Pharma — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership stake in IONIS PHARMACEUTICALS INC. As of February 9, 2024, they
• BlackRock Amends Ionis Pharma Stake as of Dec 31, 2023 — SC 13G/A · Jan 26, 2024
  BlackRock Inc. has updated its ownership stake in Ionis Pharmaceuticals Inc. as of December 31, 2023, through an SC 13G/A filing. This amendment (Amendment No.
• Ionis Pharma Signals Major Corporate Event via 8-K Filing — 8-K · Jan 22, 2024
  Ionis Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, indicating that it is using written communications under Rule 425 of the Securities Act, solicitin

Related Companies

SGEN · ALNY · PTCT

Frequently Asked Questions